Aravive Inc. (NASDAQ: ARAV) dropped 2.68% despite the company announcing positive initial results of the Phase 1b of the Phase 1b/2 trial in patients with clear cell renal cell carcinoma who received 15mg/kg of AVB-500 in combination with cabozantinib. Results from three study patients demonstrated that AVB-500 had favorable tolerability without unexpected events.
Aravive releases encouraging AVB-500 study results
The company expects to increase the dosing of 15mg/kg of AVB-500 to an additional three patients based on the pharmacodynamics, pharmacokinetics, and safety results at this dose and subject to the Data and Safety Monitoring approval Board. In the Phase 1b trial, the company plans to study greater dosages of AVB-500 to gain further safety, pharmacodynamics, and pharmacokinetics data.
Gail McIntyre, Aravive CEO, said they are delighted to report encouraging findings from the first cohort of their Phase 1b AVB-500 study in clear renal cell carcinoma. McIntyre said that they continue to evaluate AVB-500 and its ability to resolve the urgent unmet medical needs for patients suffering from clear cell renal cell carcinoma who have low survival rates.
Most importantly, with AVB-500, Revive is focusing on challenging to treat and life-threatening cancers. McIntyre said that besides the clear cell renal cell carcinoma clinical study, the company’s paclitaxel ovarian cancer lead indication is in the third phase clinical study. Recently the company said it would commence phase 1b/2 study in first-line metastatic pancreatic cancer in the second half of 2021.
Aravive commenced study in March
In March 2021, Aravive began the Phase 1b part of the AVB-500 Phase 1b/2 study in ccRCC. The study sought to examine AVB-500 in combination with cabozantinib. Phase 1b part of the clinical trial is expected to enroll up to 18 patients in three dosing groups. The Phase 2 portion of the clinical trial is scheduled to enroll up to 45 patients.